A Systematic Approach to Treatment-Associated Mesenchymal Stem Cells in Alzheimer's Disease
DOI:
https://doi.org/10.12970/2310-8231.2021.09.01Keywords:
Mesenchymal Stem Cells, Alzheimer Disease, Clinical Trials, Infusion, Dementia.Abstract
Human neurological disorders such as Alzheimer's disease (AD), are caused by neuron loss in the central nervous system, affecting memory, learning, and is the most common cause of dementia in the elderly. Currently, the use of mesenchymal stem cell (MSC)-based technologies and therapies have become the focus of research and investigations to treat AD, due to the diverse benefits on various cellular mechanisms such as neural cell replacement and cell modulations performed in clinical trials on animal subjects, thus MSC cell therapy becomes a promising and efficient alternative therapy for the development of a reliable therapeutic tool for AD in humans. We describe through review the potential use of mesenchymal stem cells for AD treatment. This is a review, following PRISMA rules for systematic reviews. MSCs therapy has been presented as a strategy for the replacement or regeneration of neural cells for AD patients. The pre-clinical results observed are recent in MSC-based therapies, therefore, few human clinical trials are in progress, recommending more clinical human trials with MSCs for the discovery and revolution of AD, since, there is still no cure and the number of people with AD has increased in recent years.
References
Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 2014; 76 Pt A: 27-50. https://doi.org/10.1016/j.neuropharm.2013.07.004
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012. 148: 1204-1222. https://doi.org/10.1016/j.cell.2012.02.040
Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimer's disease from risk factors to prevention. Biochem Pharmacol 2014; 88: 661-670. https://doi.org/10.1016/j.bcp.2014.01.003
Delbeuck X, Van der Linden M, Collette F. Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev 2003; 13: 79-92. https://doi.org/10.1023/a:1023832305702
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185. https://doi.org/10.1126/science.1566067
Paula VJR, Guimarães FM, Forlenza OV. The role of Tau protein in the pathophysiology of frontotemporal dementia. Rev Psiquiatr Clín 2009; 36: 197-202. https://doi.org/10.1590/S0101-60832009000500004
Cirrito JR, Holtzman DM. Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details. J Clin Invest 2003; 12: 321-323. https://doi.org/10.1172/JCI19420
Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363; 2105-15. https://doi.org/10.1016/S0140-6736(04)16499-4
Solomon B. Immunological approaches as therapy for Alzheimer's disease. Expert Opin Biol Ther 2020; 2: 907-17. https://doi.org/10.1517/14712598.2.8.907
Kumar S. Memantine: pharmacological properties and clinical uses. Neurol India 2004; 52: 307-09. Available from: https://pubmed.ncbi.nlm.nih.gov/15472417/
Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003; 20: 465- 76. https://doi.org/10.2165/00002512-200320060-00005
Zemek F, Drtinova L, Nepovimova E, et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014; 13: 759-774. https://doi.org/10.1517/14740338.2014.914168
Edwards Iii GA, Gamez N, Escobedo G Jr, Calderon O, Moreno-Gonzalez I. Modifiable risk factors for Alzheimer's disease. Front Aging Neurosci 2019; 11: 146. https://doi.org/10.3389/fnagi.2019.00146
Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12. https://doi.org/10.1186/1478-811X-9-12
Zhang H, Huang Z, Xu Y, Zhang S. Differentiation and neurological benefit of the mesenchymal stem cells transplanted into the rat brain following intracerebral hemorrhage. Neurol Res 2006; 28. https://doi.org/104-112.10.1179/016164106X91960
Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198: 54-64. https://doi.org/10.1016/j.expneurol.2005.10.029
Yoo SW, Kim SS, Lee SY, et al. Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newborn cells in a rat stroke model. Exp Mol Med 2008; 40: 387-397. https://doi.org/10.3858/emm.2008.40.4.387
Hamada H, Kobune M, Nakamura K, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96: 149-156. https://doi.org/10.1111/j.1349-7006.2005.00032.x
Dezawa M. Systematic neuronal and muscle induction systems in bone marrow stromal cells: the potential for tissue reconstruction in neurodegenerative and muscle degenerative diseases. Med Mol Morphol 2008; 41: 14-19. https://doi.org/10.1007/s00795-007-0389-0
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane handbook for systematic reviews of interventionsversion 5.2.0 (updated June2017), Cochrane, 2017. Available from: www.training.cochrane.org/handbook
Zhan Y, Zheng H, Wang C, et al. A novel presenilin 1 mutation (F388L) identified in a Chinese family with earlyonset Alzheimer’s disease. Neurobiol Aging 2017; 50: 168.e1-168.e4. https://doi.org/10.1016/j.neurobiolaging.2016.10.010
Filadi R, Pizzo P. Defective autophagy and Alzheimer’s disease: is calcium the key? Neural Regen Res 2019; 14: 2081-2082. https://doi.org/10.4103/1673-5374.262584
Xu X. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis 2009; 16: 211-224. https://doi.org/10.3233/JAD-2009-0957
Chabrier MA, Cheng D, Castello NA, Green KN, LaFerla FM. Synergistic effects of amyloid-beta and wild-type human Tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol Dis 2014; 64: 107-117. https://doi.org/10.1016/j.nbd.2014.01.007
Zhang FQ, Jiang JL, Zhang JT, Niu H, Fu XQ, Zeng LL. Current status and future prospects of stem cell therapy in Alzheimer's disease. Neural Regen Res 2020; 15: 242-250. https://doi.org/10.4103/1673-5374.265544
Bonda DJ, Wang X, Lee HG, Smith MA, Perry G, Zhu X. Neuronal failure in Alzheimer's disease: a view through theoxidative stress looking-glass. Neurosci Bull 2014; 30: 243-252. https://doi.org/10.1007/s12264-013-1424-x
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-333. https://doi.org/10.1056/NEJMoa1304839
Duncan T, Valenzuela M. Alzheimer's disease, dementia, and stem cell therapy. Stem Cell Res Ther 2017; 8: 111. https://doi.org/10.1186/s13287-017-0567-5
Palmer AM. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 2011; 32: 141-147. https://doi.org/10.1016/j.tips.2010.12.007
Wyse RD, Dunbar GL, Rossignol J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci 2014; 15: 1719-1745. https://doi.org/10.3390/ijms15021719
Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20: 1297-308. https://doi.org/10.1089/scd.2010.0466
Oh SH, Kim HN, Park HJ, Shin JY, Lee PH. Mesenchymal stem cells increase hippocampal neurogenesis and neuronal differentiation by enhancing the Wnt signaling pathway in an Alzheimer's disease model. Cell Transplant 2015; 24: 1097- 1109. https://doi.org/10.3727/096368914X679237
Divya MS, Roshin GE, Divya TS, et al. Umbilical cord bloodderived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. Stem Cell Res Ther 2012; 3: 57. https://doi.org/10.1186/scrt148
Park D, Yang G, Bae DK, et al. Human adipose tissuederived mesenchymal stem cells improve cognitive function and physical activity in ageing mice. J Neurosci Res 2013; 91: 660-670. https://doi.org/10.1002/jnr.23182
Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJ. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A 2005; 102: 18171-18176. https://doi.org/10.1073/pnas.0508945102
Zilka N, Zilkova M, Kazmerova Z, Sarissky M, Cigankova V, Novak M. Mesenchymal stem cells rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated Tau. Neuroscience 2011; 193: 330-337. https://doi.org/10.1016/j.neuroscience.2011.06.088
Kim JY, Kim DH, Kim JH, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ 2012; 19: 680-691. https://doi.org/10.1038/cdd.2011.140
Kim KS, Kim HS, Park JM, et al. Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer's disease model. Neurobiol Aging 2013; 34: 2408- 2420. https://doi.org/10.1016/j.neurobiolaging.2013.03.029
Yun H, Kim H, Park K, et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an A1–42-infused mouse model of Alzheimer's disease. Cell Death Dis 2013; 4: e958. https://doi.org/10.1038/cddis.2013.490
Teixeira FG, Carvalho MM, Neves-Carvalho A, et al. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev Rep 2015; 11: 288-297. https://doi.org/10.1007/s12015-014-9576-2
Naaldijk Y, Jäger C, Fabian C, et al. Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathol Appl Neurobiol 2017; 43: 299-314. https://doi.org/10.1111/nan.12319
Yang H, Xie Z, Wei L, et al. Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse model. Stem Cell Res Ther 2013; 4: 76. https://doi.org/10.1186/scrt227
Kwak KA, Lee SP, Yang JY, Park YS. Current perspectives regarding stem cell-based therapy for Alzheimer's disease. Stem Cells Int 2018; 2018: 6392986. https://doi.org/10.1155/2018/6392986
Li M, Guo K, Ikehara S. Stem cell treatment for Alzheimer’s disease. Int J Mol Sci 2014; 15: 19226-19238. https://doi.org/10.3390/ijms151019226
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. https://doi.org/10.1182/blood-2004-04-1559
Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214-2219. https://doi.org/10.1182/blood-2004-07-2921
Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76. https://doi.org/10.1097/01.tp.0000244572.24780.54
Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-363. https://doi.org/10.1111/j.1365-2249.2007.03422.x
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74- 85. https://doi.org/10.1634/stemcells.2004-0359
Chen J, Tang YX, Liu YM, et al. Transplantation of adiposederived stem cells is associated with neural differentiation and functional improvement in a rat model of intracerebral hemorrhage. CNS Neurosci Ther 2012; 18: 847-854. https://doi.org/10.1111/j.1755-5949.2012.00382.x
Case J, Horvath TL, Ballas CB, March KL, Srour EF. In vitro clonal analysis of murine pluripotent stem cells isolated from skeletal muscle and adipose stromal cells. Exp Hematol 2008; 36: 224-234. https://doi.org/10.1016/j.exphem.2007.09.003
Peroni D, Scambi I, Pasini A, et al. Stem molecular signature of adipose-derived stromal cells. Exp Cell Res 2008; 314: 603-615. https://doi.org/10.1016/j.yexcr.2007.10.007
Gutiérrez-Fernández M, Rodríguez-Frutos B, Ramos-Cejudo J, et al. Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther 2013; 4: 11. https://doi.org/10.1186/scrt159
Ikegame Y, Yamashita K, Hayashi S, et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011; 13: 675-685. https://doi.org/10.3109/14653249.2010.549122
Leu S, Lin YC, Yuen CM, et al. Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med 2010; 8: 63. https://doi.org/10.1186/1479-5876-8-63
Lu S, Lu C, Han Q, et al. Adipose-derived mesenchymal stem cells protect PC12 cells from glutamate excitotoxicityinduced apoptosis by upregulation of XIAP through PI3-K/Akt activation. Toxicology 2011; 279: 189-195. https://doi.org/10.1016/j.tox.2010.10.011
Wei X, Zhao L, Zhong J, et al. Adipose stromal cells-secreted neuroprotective media against neuronal apoptosis. Neurosci Lett 2009; 462: 76-79. https://doi.org/10.1016/j.neulet.2009.06.054
Yang KL, Lee JT, Pang CY, et al. Human adipose-derived stem cells for the treatment of intracerebral hemorrhage in rats via femoral intravenous injection. Cell Mol Biol Lett 2012; 17: 376-392. https://doi.org/10.2478/s11658-012-0016-5
Kang JM, Yeon BK, Cho SJ, Suh YH. Stem cell therapy for Alzheimer's disease: a review of recent clinical trials. J Alzheimers Dis 2016; 54: 879-889. https://doi.org/10.3233/JAD-160406
Darlington D, Deng J, Giunta B, et al. Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in Alzheimer mice. Stem Cells Dev 2013; 22: 412-421. https://doi.org/10.1089/scd.2012.0345
Mendrone Jr A. Peripheral blood as a source of stem cells. Rev Bras Hematol Hemoter 2009; 31: 19-24. https://doi.org/10.1590/S1516-84842009005000026
Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010; 5: 933-946. https://doi.org/10.2217/rme.10.72
Fesharaki M, Razavi S, Ghasemi-Mobarakeh L, et al. Differentiation of human scalp adipose-derived mesenchymal stem cells into mature neural cells on electrospun nanofibrous scaffolds for nerve tissue engineering applications. Cell J 2018; 20: 168-176. https://doi.org/10.22074/cellj.2018.4898
Bali P, Lahiri DK, Banik A, Nehru B, Anand A. Potential for stem cells therapy in Alzheimer’s disease: do neurotrophic factors play critical role? Curr Alzheimer Res 2017; 14: 208- 220. https://doi.org/10.2174/1567205013666160314145347
Cui GH, Wu J, Mou FF, et al. Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice. FASEB J 2018; 32: 654-668. https://doi.org/10.1096/fj.201700600R
Park SE, Lee J, Chang EH, et al. Activin A secreted by human mesenchymal stem cells induces neuronal development and neurite outgrowth in an in vitro model of Alzheimer’s disease: neurogenesis induced by MSCs via activin A. Arch Pharm Res 2016; 39: 1171-1179. https://doi.org/10.1007/s12272-016-0799-4
Liew LC, Katsuda T, Gailhouste L, Nakagama H, Ochiya T. Mesenchymal stem cell-derived extracellular vesicles: a glimmer of hope in treating Alzheimer’s disease. Int Immunol 2017; 29: 11-19. https://doi.org/10.1093/intimm/dxx002
Tan XF, Qin JB, Jin GH, et al. Effects of Brn-4 on the neuronal differentiation of neural stem cells derived from rat midbrain. Cell Biol Int 2010; 34: 877-882. https://doi.org/10.1042/CBI20100214
Liu Z, Wang C, Wang X, Xu S. Therapeutic effects of transplantation of as-miR-937-expressing mesenchymal stem cells in murine model of Alzheimer’s disease. Cell Physiol Biochem 2015; 37: 321-330. https://doi.org/10.1159/000430356
Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821-7. https://doi.org/10.1124/jpet.102.041616
Baumel B. Alzheimer's disease stem cells multiple infusions. ClinicalTrials.gov 2019. Available from: https://clinicaltrials. gov/ct2/show/study/NCT04040348
Santosh K. Allogeneic human mesenchymal stem cells for Alzheimer's disease. ClinicalTrials.gov 2016. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02833792
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749. https://doi.org/10.1634/stemcells.2007-0197
Kim HJ, Seo SW, Chang JW, et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial. Alzheimers Dement (N Y) 2015; 1: 95-102. https://doi.org/10.1016/j.trci.2015.06.007
Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World J Stem Cells 2020; 12: 787-802. https://doi.org/10.4252/wjsc.v12.i8.787
Shruster A, Melamed E, Offen D. Neurogenesis in the aged and neurodegenerative brain. Apoptosis 2010; 15: 1415- 1421. https://doi.org/10.1007/s10495-010-0491-y
Salem AM, Ahmed HH, Atta HM, Ghazy MA, Aglan HA. Potential of bone marrow mesenchymal stem cells in management of Alzheimer’s disease in female rats. Cell Biol Int 2014; 38: 1367-1383. https://doi.org/10.1002/cbin.10331
Sadatpoor SO, Salehi Z, Rahban D, Salimi A. Manipulated mesenchymal stem cells applications in neurodegenerative diseases. Int J Stem Cells 2020; 13: 24-45. https://doi.org/10.15283/ijsc19031
